Reddy K Sudhakar, Stablein Don, Taranto Sarah, Stratta Robert J, Johnston Thomas D, Waid Thomas H, McKeown J Wade, Lucas Bruce A, Ranjan Dinesh
Departments of Surgery and Medicine, University of Kentucky, Lexington, KY, USA.
Am J Kidney Dis. 2003 Feb;41(2):464-70. doi: 10.1053/ajkd.2003.50057.
Pancreas transplantation improves quality of life and prevents the progression of secondary complications of diabetes. Whether these benefits translate into a long-term survival advantage is not entirely clear.
Using the United Network for Organ Sharing database, we analyzed long-term survival in 18,549 patients with type 1 diabetes and renal failure who received a kidney transplant between 1987 and 1996. Patient survival was calculated using the Kaplan-Meier method. Proportional hazards models were used to adjust for effects of differences in recipient and donor variables between simultaneous kidney-pancreas transplants (SKPTs) and kidney-alone transplants.
SKPT and living donor kidney recipients had a significant crude survival distribution advantage over cadaver kidney transplant recipients (8-year survival rates: 72% for SKPT recipients, 72% for living donor kidney recipients, and 55% for cadaver kidney recipients). The survival advantage for SKPT recipients over cadaver kidney recipients diminished, but persisted after adjusting for donor and recipient variables and kidney graft function as time-varying covariates. SKPT recipients had a high mortality risk relative to living donor kidney recipients through 18 months posttransplantation (hazards ratio, 2.2; P < 0.001), but had a lower relative risk (hazard ratio, 0.86; P < 0.02) thereafter. In SKPT recipients, maintenance of a functioning pancreas graft was associated with a survival benefit.
The long-term survival of SKPT recipients is superior to that of cadaver kidney transplant recipients with type 1 diabetes. There is no difference in survival of SKPT recipients and living donor kidney recipients with type 1 diabetes at up to 8 years' follow-up; the former have a greater early mortality risk and the latter have a greater late mortality risk. Results of this study suggest that successful simultaneous kidney-pancreas transplantation is not only life enhancing, but life saving.
胰腺移植可改善生活质量并预防糖尿病继发并发症的进展。这些益处是否能转化为长期生存优势尚不完全清楚。
利用器官共享联合网络数据库,我们分析了1987年至1996年间接受肾移植的18549例1型糖尿病合并肾衰竭患者的长期生存情况。采用Kaplan-Meier方法计算患者生存率。使用比例风险模型来调整同时进行肾胰腺移植(SKPT)和单纯肾移植受者与供者变量差异的影响。
SKPT受者和活体供肾受者与尸体肾移植受者相比具有显著的粗生存率分布优势(8年生存率:SKPT受者为72%,活体供肾受者为72%,尸体肾受者为55%)。SKPT受者相对于尸体肾受者的生存优势有所减弱,但在将供者和受者变量以及肾移植功能作为随时间变化的协变量进行调整后仍然存在。在移植后18个月内,SKPT受者相对于活体供肾受者有较高的死亡风险(风险比,2.2;P<0.001),但此后相对风险较低(风险比,0.86;P<0.02)。在SKPT受者中,胰腺移植功能的维持与生存获益相关。
SKPT受者的长期生存率优于1型糖尿病尸体肾移植受者。在长达8年的随访中,1型糖尿病SKPT受者和活体供肾受者的生存率无差异;前者早期死亡风险较高,后者晚期死亡风险较高。本研究结果表明,成功的同时肾胰腺移植不仅能提高生活质量,还能挽救生命。